Tauroursodeoxycholic acid
Spécifications
14605-22-2Numéro CAS
987-160-3Numéro CE
2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acidNom IUPAC
C26H45NO6SFormule chimique
499.7 g/molMasse molaire
Tauroursodeoxycholic acid; 14605-22-2; TUDCA; Ursodeoxycholyltaurine; Taurursodiol; ursodoxicoltaurine; Taurolite; UR 906; Tauroursodesoxycholic acid; Ur-906; 60EUX8MN5X; N-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)-taurine; CHEBI:80774; N-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)taurine; 3alpha,7beta-dihydroxy-5beta-cholanoyltaurine; 2-[(4R)-4-[(1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid; 2-((4R)-4-((1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-dihydroxy-2,15-dimethyltetracyclo(8.7.0.0^(2,7).0^(11,15))heptadecan-14-yl)pentanamido)ethane-1-sulfonic acid; RefChem:187542; tauroursodeoxycholic acid, (3alpha,5alpha,7alpha)-; tauroursodeoxycholic acid, monosodium salt, (3alpha,5beta,7alpha)-; Ursodeoxy cholic acid; Taurursodiol [USAN]; CHEMBL272427; Taurursodiol (USAN); ursodoxicoltaurine (INN); 2-[[(3alpha,5beta,7beta)-3,7-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic acid; 2-((R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid; URSODOXICOLTAURINE [INN]; 2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid; 2-{[(3alpha,5beta,7alpha,8alpha,14beta,17alpha)-3,7-Dihydroxy-24-Oxocholan-24-Yl]amino}ethanesulfonic Acid; MFCD00065451; TUDCA;UR 906;Taurolite; C26H45NO6S; UNII-60EUX8MN5X; MFCD00069496; ST 24:1;O3;T; TUDA; N-ursodeoxycholoyltaurine; tauro-ursodeoxycholic acid; Ursodeoxycholic acid-taurin; SCHEMBL40764; GTPL4746; orb1226230; orb1305349; Tauroursodeoxycholic acid;TUDCA; DTXSID80932754; EX-A730; 2-(((3-alpha,5-beta,7-beta)-3,7-Dihydroxy-24-oxocholan-24-yl) amino)ethanesulfonic acid; BHTRKEVKTKCXOH-LBSADWJPSA-N; HMS3885C19; URSODOXICOLTAURINE [WHO-DD]; MSK10383; Taurine, N-(3-alpha,7-beta-dihydroxy-5-beta-cholan-24-oyl)-,; BDBM50236230; LMST05040015; Sodium tauroursodeoxycholate, >=95%; WHO 11388; AKOS040746761; CCG-269687; DB08834; FT03670; 2-(((3-alpha,5-beta,7-beta)-3,7-Dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic acid; 2-[(3alpha,7beta-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic acid; AC-34539; DA-58311; HY-19696; SY073014; CS-0016289; NS00069560; T2532; D11836; Relyvrio (sodium phenylbutyrate + taurursodiol); F811909; Q7688907; Ursodoxicoltaurine for impurity B identification CRS; 3,7-Dihydroxy-N-(2-sulfoethyl)cholan-24-imidic acid; BRD-K45245728-335-01-4; 3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLANOYLTAURINE; N-(2-Sulfoethyl)-3| cent,7|?-dihydroxy-5|?-cholan-24-amide; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid N-(2-sulfoethyl)amide; 2-[(3alpha,7beta-Dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethane-1-sulfonic acid; 2-[[(3|A,5|A,7|A)-3,7-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic acid; 2-{[(3alpha,5beta,7beta)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethane-1-sulfonic acid; Tauroursodeoxycholate; TUDCA; 3alpha,7beta-dihydroxy-5beta-cholanoyl Taurine; 2-((R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid; 2-((R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid; Ethanesulfonic acid, 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-Synonymes